TWiV 707: COVID-19 clinical update #45 with Dr. Daniel Griffin

January 16, 2021

In COVID-19 clinical update #45, Daniel Griffin discusses J&J Ad26 vaccine results, reactogenicity after the second dose of mRNA vaccines, expansion of vaccine eligibility, and the finding that encephalitis after SARS-CoV-2 infection is a cytokine release syndrome.

Hosts: Daniel Griffin and Vincent Racaniello

Click arrow to play
Download TWiV 707 (24 MB .mp3, 40 min)
Subscribe (free): iTunesGoogle PodcastsRSSemail

Become a patron of TWiV!

Links for this episode

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to

Leave a Reply

Your email address will not be published. Required fields are marked *

One comment on “TWiV 707: COVID-19 clinical update #45 with Dr. Daniel Griffin

  1. John Hempel Jan 16, 2021

    Wouldn’t another reason for delaying vaccination for some time after having received the monoclonal be that you don’t want the Spike protein resulting from the vaccine to be consumed by circulating monoclonals before it has a chance to be taken up by the immune system and start to elicit antibody production?

    Relatedly, I assume that the half-life of the RNA from the Pfizer & Moderna vaccines is known, and that it’s not more than a day or so, but I don’t recall specifically hearing that.